Please use this identifier to cite or link to this item:
https://hdl.handle.net/10356/86185
Title: | Patient with multiple acyl-CoA dehydrogenase deficiency disease and ETFDH mutations benefits from riboflavin therapy : a case report | Authors: | Goh, Liuh Ling Lee, Yingshan Tan, Ee Shien Lim, James Soon Chuan Lim, Chia Wei Dalan, Rinkoo |
Keywords: | ETFDH Lipid Storage Myopathy |
Issue Date: | 2018 | Source: | Goh, L. L., Lee, Y., Tan, E. S., Lim, J. S. C., Lim, C. W., & Dalan, R. (2018). Patient with multiple acyl-CoA dehydrogenase deficiency disease and ETFDH mutations benefits from riboflavin therapy : a case report. BMC Medical Genomics, 11(1), 37-. | Series/Report no.: | BMC Medical Genomics | Abstract: | Background: Lipid storage myopathy (LSM) is a diverse group of lipid metabolic disorders with great variations in the clinical phenotype and age of onset. Classical multiple acyl-CoA dehydrogenase deficiency (MADD) is known to occur secondary to mutations in electron transfer flavoprotein dehydrogenase (ETFDH) gene. Whole exome sequencing (WES) with clinical correlations can be useful in identifying genomic alterations for targeted therapy. Case presentation: We report a patient presented with severe muscle weakness and exercise intolerance, suggestive of LSM. Diagnostic testing demonstrated lipid accumulation in muscle fibres and elevated plasma acyl carnitine levels. Exome sequencing of the proband and two of his unaffected siblings revealed compound heterozygous mutations, c.250G > A (p.Ala84Thr) and c.770A > G (p.Tyr257Cys) in the ETFDH gene as the probable causative mutations. In addition, a previously unreported variant c.1042C > T (p.Arg348Trp) in ACOT11 gene was found. This missense variant was predicted to be deleterious but its association with lipid storage in muscle is unclear. The diagnosis of MADD was established and the patient was treated with riboflavin which resulted in rapid clinical and biochemical improvement. Conclusions: Our findings support the role of WES as an effective tool in the diagnosis of highly heterogeneous disease and this has important implications in the therapeutic strategy of LSM treatment. | URI: | https://hdl.handle.net/10356/86185 http://hdl.handle.net/10220/45251 |
DOI: | 10.1186/s12920-018-0356-8 | Schools: | Lee Kong Chian School of Medicine (LKCMedicine) | Rights: | © 2018 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. | Fulltext Permission: | open | Fulltext Availability: | With Fulltext |
Appears in Collections: | LKCMedicine Journal Articles |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Patient with multiple acyl-CoA dehydrogenase deficiency disease and ETFDH mutations benefits from riboflavin therapy.pdf | 1.1 MB | Adobe PDF | View/Open |
SCOPUSTM
Citations
20
19
Updated on Mar 27, 2024
Web of ScienceTM
Citations
20
14
Updated on Oct 25, 2023
Page view(s)
320
Updated on Mar 27, 2024
Download(s) 50
93
Updated on Mar 27, 2024
Google ScholarTM
Check
Altmetric
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.